[go: up one dir, main page]

ATE267006T1 - Polyetherester-copolymere als matrixmaterial für die arzneistoffabgabe - Google Patents

Polyetherester-copolymere als matrixmaterial für die arzneistoffabgabe

Info

Publication number
ATE267006T1
ATE267006T1 AT02077025T AT02077025T ATE267006T1 AT E267006 T1 ATE267006 T1 AT E267006T1 AT 02077025 T AT02077025 T AT 02077025T AT 02077025 T AT02077025 T AT 02077025T AT E267006 T1 ATE267006 T1 AT E267006T1
Authority
AT
Austria
Prior art keywords
drug delivery
matrix material
polyetherester copolymers
polyetherester
glycol
Prior art date
Application number
AT02077025T
Other languages
English (en)
Inventor
Jacob Hildebrand Goedemoed
Wilhelmus Everhardus Hennink
Jeroen Mattijs Bezemer
Jan Feijen
Blitterswijk Clemens Van
Bruijn Joost Dick De
Original Assignee
Chienna Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chienna Bv filed Critical Chienna Bv
Application granted granted Critical
Publication of ATE267006T1 publication Critical patent/ATE267006T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02077025T 1996-08-16 1997-08-18 Polyetherester-copolymere als matrixmaterial für die arzneistoffabgabe ATE267006T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/699,896 US5980948A (en) 1996-08-16 1996-08-16 Polyetherester copolymers as drug delivery matrices

Publications (1)

Publication Number Publication Date
ATE267006T1 true ATE267006T1 (de) 2004-06-15

Family

ID=24811379

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97202533T ATE255884T1 (de) 1996-08-16 1997-08-18 Polyätherester-copolymere als matrixmaterialien für die arzneistoffabgabe
AT02077025T ATE267006T1 (de) 1996-08-16 1997-08-18 Polyetherester-copolymere als matrixmaterial für die arzneistoffabgabe

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT97202533T ATE255884T1 (de) 1996-08-16 1997-08-18 Polyätherester-copolymere als matrixmaterialien für die arzneistoffabgabe

Country Status (9)

Country Link
US (1) US5980948A (de)
EP (2) EP1247522B1 (de)
AT (2) ATE255884T1 (de)
CA (1) CA2213368C (de)
DE (2) DE69729228T2 (de)
DK (2) DK1247522T3 (de)
ES (2) ES2212037T3 (de)
PT (2) PT830859E (de)
WO (1) WO1998006439A1 (de)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842657A1 (de) * 1996-11-19 1998-05-20 OctoPlus B.V. Mikrosphären zur gesteuerten Freisetzung und Verfahren zur Herstellung dieser Mikrosphären
FR2777895A1 (fr) * 1998-04-28 1999-10-29 Debio Rech Pharma Sa Polymere sequence non-reticule,procede pour sa preparation, et ses utilisations
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6656489B1 (en) 1999-02-10 2003-12-02 Isotis N.V. Scaffold for tissue engineering cartilage having outer surface layers of copolymer and ceramic material
EP1038538A1 (de) * 1999-03-19 2000-09-27 IsoTis B.V. Verfahren zur Regeneration von Muskelgewebe
JP2002542183A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 成形可能な乾燥した医薬製剤
EP1068872A1 (de) * 1999-07-12 2001-01-17 IsoTis B.V. Nahtmaterialen
JP2001054563A (ja) * 1999-07-12 2001-02-27 Isotis Bv 縫合糸
WO2001010414A1 (en) * 1999-08-04 2001-02-15 Oakwood Laboratories L.L.C. Slow release microspheres
ATE381357T1 (de) * 1999-08-06 2008-01-15 Chienna Bv Formen von polymeren
EP1090928B1 (de) * 1999-09-30 2004-05-26 Chienna B.V. Mit bioaktiven Mitteln beladene Polymeren
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US20050214327A1 (en) * 2000-06-02 2005-09-29 Allergan, Inc. Neurotoxin-containing suppositories and related methods
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
AU2001281729A1 (en) * 2000-07-14 2002-01-30 Novo-Nordisk A/S Method of moulding a pharmaceutical composition in a packaging material
EP1247537A1 (de) * 2001-04-04 2002-10-09 Isotis B.V. Beschichtung für medizinische Vorrichtungen
US6565884B2 (en) 2001-09-10 2003-05-20 Interpore Cross International Bone graft material incorporating demineralized bone matrix and lipids
US7357947B2 (en) * 2001-09-10 2008-04-15 Biomet, Inc. Bone graft material incorporating demineralized bone matrix and lipids
CA2466998A1 (en) * 2001-11-12 2003-05-22 Alkermes Controlled Therapeutics, Inc. Biocompatible polymer blends and uses thereof
US8454997B2 (en) 2001-12-18 2013-06-04 Novo Nordisk A/S Solid dose micro implant
JP2005518469A (ja) * 2002-02-26 2005-06-23 シエンナ ビー．ブイ． 生体臨床学用途のための生分解性ポリマー状物質
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
AU2003249244A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Methods for the treatment of neoplasms
US6926919B1 (en) * 2003-02-26 2005-08-09 Advanced Cardiovascular Systems, Inc. Method for fabricating a coating for a medical device
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
US20040215318A1 (en) * 2003-04-24 2004-10-28 Brian Kwitkin Timed delivery of therapeutics to blood vessels
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
CA2575740A1 (en) 2004-03-24 2005-10-13 Doctor's Research Group, Inc. Methods of performing medical procedures that promote bone growth, methods of making compositions that promote bone growth, and apparatus for use in such methods
EP2329852A1 (de) 2004-03-26 2011-06-08 SurModics, Inc. Zusammensetzung und Verfahren zur Herstellung von biokompatiblen Oberflächen
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006002366A2 (en) * 2004-06-24 2006-01-05 Surmodics, Inc. Biodegradable ocular devices, methods and systems
US20060018948A1 (en) * 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US7311980B1 (en) * 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0426822D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
MX2007007587A (es) 2004-12-22 2007-12-11 Ambrx Inc Formulaciones de la hormona del crecimiento humano que comprenden un aminoacido codificado de manera no natural.
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
SG161210A1 (en) 2004-12-22 2010-05-27 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
MX2007007581A (es) * 2004-12-22 2007-07-24 Ambrx Inc Composiciones de amino acil-arnt sintetasa y sus usos.
US20060147491A1 (en) * 2005-01-05 2006-07-06 Dewitt David M Biodegradable coating compositions including multiple layers
US20060198868A1 (en) * 2005-01-05 2006-09-07 Dewitt David M Biodegradable coating compositions comprising blends
EP1679065A1 (de) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Zubereitung mit kontrollierter Freisetzung von Interferon auf PEGT/PBT-Block-Copolymer-Basis
CN101247821B (zh) * 2005-06-03 2013-01-23 Ambrx公司 经改良人类干扰素分子和其用途
DK1937824T3 (da) 2005-08-18 2013-04-02 Ambrx Inc Sammensætninger af tRNA og anvendelser deraf
SI1954710T1 (sl) * 2005-11-08 2011-08-31 Ambrx Inc Pospeĺ evala za modifikacijo nenaravnih aminokislin in nenaravnih peptidov aminokislin
CN106443006A (zh) * 2005-11-16 2017-02-22 Ambrx公司 包括非天然氨基酸的方法和组合物
AU2006318696A1 (en) 2005-11-17 2007-05-31 Zogenix, Inc. Delivery of viscous formulations by needle-free injection
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
JP2009542671A (ja) * 2006-06-28 2009-12-03 サーモディクス，インコーポレイティド 微粒子を含む活性剤溶出マトリックス
US9133495B2 (en) * 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
EP2615108B1 (de) 2006-09-08 2016-10-26 Ambrx, Inc. Modifiziertes humanes Plasmapolypeptid oder Fc-Gerüste und deren Verwendungen
NZ574960A (en) * 2006-09-08 2012-02-24 Ambrx Inc Suppressor trna transcription in vertebrate cells
US20080138397A1 (en) * 2006-10-24 2008-06-12 Aradigm Corporation Processes for taste-masking of inhaled formulations
US20080154241A1 (en) * 2006-12-07 2008-06-26 Burkstrand Michael J Latent stabilization of bioactive agents releasable from implantable medical articles
PT2068909E (pt) 2007-03-30 2012-07-04 Ambrx Inc Polipéptidos fgf-21 modificados e suas utilizações
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
EP2152743A2 (de) 2007-05-23 2010-02-17 Allergan, Inc. Quervernetztes collagen und anwendungen davon
US20090022805A1 (en) * 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
US8709827B2 (en) * 2007-06-28 2014-04-29 Surmodics, Inc. Polypeptide microparticles
EP2175865A4 (de) * 2007-07-25 2012-01-11 Biolex Therapeutics Inc Interferon-arzneiprodukte mit kontrollierter freisetzung und behandlung von hcv-infektionen damit
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
US9138509B2 (en) * 2007-09-14 2015-09-22 Musculoskeletal Transplant Foundation Composition for filling bone defects
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
EP2055299A1 (de) 2007-10-23 2009-05-06 Koninklijke Philips Electronics N.V. Verfahren zur Herstellung von Polymermikropartikeln
KR101577471B1 (ko) 2007-11-16 2015-12-14 알러간, 인코포레이티드 자색반병의 치료를 위한 조성물 및 방법
JP5547083B2 (ja) * 2007-11-20 2014-07-09 アンブルックス，インコーポレイテッド 修飾されたインスリンポリペプチドおよびそれらの使用
US8394782B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US8394784B2 (en) 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
DE102007062113B4 (de) * 2007-12-21 2011-05-12 Bettina Lingenfelder Dermatologische Zubereitung
JP5330407B2 (ja) * 2007-12-21 2013-10-30 スリーエム イノベイティブ プロパティズ カンパニー 再帰反射性舗装マーキング
US9314524B2 (en) * 2007-12-31 2016-04-19 Calla Therapeutics Llc Topical formulations of Flucytosine
US20090186059A1 (en) * 2008-01-14 2009-07-23 Johnson Elizabeth E Devices and methods for elution of nucleic acid delivery complexes
US9938333B2 (en) 2008-02-08 2018-04-10 Ambrx, Inc. Modified leptin polypeptides and their uses
JP5667559B2 (ja) 2008-03-28 2015-02-12 サーモディクス，インコーポレイティド 微粒子が配置された弾性基質を有する挿入可能な医療機器、および薬物送達方法
WO2009126830A2 (en) * 2008-04-09 2009-10-15 Surmodics, Inc. Delivery of nucleic acid complexes from materials including negatively charged groups
WO2009128944A2 (en) * 2008-04-18 2009-10-22 Surmodics, Inc. Coating systems for the controlled delivery of hydrophilic bioactive agents
EP2273880B1 (de) * 2008-04-28 2014-12-31 Zogenix, Inc. Neuartige formulierungen zur behandlung von migräne
US8936811B2 (en) * 2008-05-07 2015-01-20 Surmodics, Inc. Device coated with glycogen particles comprising nucleic acid complexes
US20100008966A1 (en) * 2008-07-14 2010-01-14 Surmodics, Inc. Medical Devices and Methods for Delivery of Nucleic Acids
AU2009274076C1 (en) 2008-07-23 2014-04-17 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
AU2009288118B2 (en) 2008-09-02 2014-12-11 Allergan, Inc. Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
CN102177237B (zh) 2008-09-12 2013-10-30 金沃特公司 用于贮存和稳定生物分子的基质和介质
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
NZ601659A (en) 2008-09-26 2014-02-28 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
CA2758260A1 (en) * 2009-04-08 2010-10-14 Surmodics, Inc. Controlled release devices and methods for delivery of nucleic acids
WO2010118213A2 (en) 2009-04-08 2010-10-14 Surmodics, Inc. Particles for delivery of nucleic acids and related devices and methods
US8246576B2 (en) 2009-05-18 2012-08-21 Surmodics, Inc. Method and apparatus for delivery of a therapeutic agent with an expandable medical device
JP2013515081A (ja) 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
BR112012015461A2 (pt) 2009-12-21 2017-01-10 Ambrx Inc polipeptídeos de somatotropina boviina modificados e seus usos
US20110159098A1 (en) * 2009-12-30 2011-06-30 Surmodics, Inc. Stabilization and delivery of nucleic acid complexes
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
CA2792729C (en) 2010-03-12 2016-06-28 Allergan Industrie, Sas Fluid compositions for improving skin conditions
DK2550027T4 (da) 2010-03-22 2019-05-13 Allergan Inc Tværbundne polysaccharid- og protein-polysaccharid-hydrogeler til blødvævsforøgelse
US20110319473A1 (en) 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
ES2628931T3 (es) 2010-07-09 2017-08-04 Innocore Technologies B.V. Copolímeros multibloque segmentados de fases separadas biodegradables y liberación de polipétidos biológicamente activos
SI2605789T1 (sl) 2010-08-17 2019-10-30 Ambrx Inc Modificirani polipeptidi relaksina in njihova uporaba
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP2621475A1 (de) 2010-10-02 2013-08-07 Link Research&Grants Corporation Behandlung von tinnitus und zugehörigen dysfunktionen des gehörs
US20120100187A1 (en) 2010-10-26 2012-04-26 Surmodics, Inc. Coatings and methods for controlled elution of hydrophilic active agents
US8901092B2 (en) 2010-12-29 2014-12-02 Surmodics, Inc. Functionalized polysaccharides for active agent delivery
US9861727B2 (en) 2011-05-20 2018-01-09 Surmodics, Inc. Delivery of hydrophobic active agent particles
US10213529B2 (en) 2011-05-20 2019-02-26 Surmodics, Inc. Delivery of coated hydrophobic active agent particles
FR2975301B1 (fr) 2011-05-20 2013-05-24 Flamel Tech Sa Composition comprenant un interferon alpha
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
KR102015676B1 (ko) 2011-06-03 2019-10-21 알러간, 인코포레이티드 항산화제를 포함하는 피부 충전제 조성물
JP2014523914A (ja) 2011-07-18 2014-09-18 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作された微生物標的化分子およびその使用
CA2842514C (en) 2011-07-22 2018-12-18 Innocore Technologies B.V. Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
EP2859017B1 (de) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
US9732161B2 (en) 2012-06-26 2017-08-15 Sutro Biopharma, Inc. Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
ES2728864T3 (es) 2012-08-31 2019-10-29 Sutro Biopharma Inc Aminoácidos modificados que comprenden un grupo azido
EP2914297B1 (de) 2012-11-05 2019-01-09 SurModics, Inc. Zusammensetzung und verfahren zur freisetzung von hydrophoben wirkstoffen
US11246963B2 (en) 2012-11-05 2022-02-15 Surmodics, Inc. Compositions and methods for delivery of hydrophobic active agents
WO2014167440A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of cyclobenzaprine or salts thereof
AU2014268603B2 (en) 2013-05-21 2018-03-22 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
FR3007972B1 (fr) 2013-07-04 2015-08-07 Oreal Composition cosmetique comprenant des esters gras liquides, des huiles volatiles et des epaississants, et procede de traitement cosmetique
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3055298B1 (de) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modifizierte aminosäuren mit funktionellen tetrazingruppen, verfahren zur herstellung und verfahren zu deren verwendung
EP3546474B1 (de) 2013-12-18 2021-07-07 President and Fellows of Harvard College Crp-erfassung/-detektion von grampositiven bakterien
WO2015150948A1 (en) 2014-03-29 2015-10-08 Wockhardt Limited Modified release solid oral pharmaceutical compositions of cyclobenzaprine or a salt thereof
US10519443B2 (en) 2014-09-08 2019-12-31 University Of Iowa Research Foundation Microrna inhibitor system and methods of use thereof
EP3200838B1 (de) 2014-09-30 2019-09-18 Allergan Industrie, SAS Stabile hydrogelzusammensetzungen mit additiven
EP3412302B1 (de) 2014-10-24 2021-05-12 Bristol-Myers Squibb Company Modifizierte fgf-21-polypeptide und verwendungen davon
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
WO2016187413A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
US10273476B2 (en) 2016-04-30 2019-04-30 University Of Iowa Research Foundation MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration
RU2617049C1 (ru) * 2016-05-12 2017-04-19 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство на основе никлозамида
US10898446B2 (en) 2016-12-20 2021-01-26 Surmodics, Inc. Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.
RU2020123346A (ru) 2017-12-20 2022-01-20 Аллерган, Инк. Полипептиды клеточносвязывающего домена ботулинического токсина и способы применения для лечения расстройств, связанных с фиброзом
EP4389145A3 (de) 2018-09-11 2024-08-21 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und deren verwendungen
WO2020082057A1 (en) 2018-10-19 2020-04-23 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
US20220226488A1 (en) 2019-02-12 2022-07-21 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US12226552B2 (en) 2019-09-30 2025-02-18 Surmodics, Inc. Active agent depots formed in situ
KR20220151202A (ko) 2020-03-11 2022-11-14 암브룩스, 인코포레이티드 인터류킨-2 폴리펩타이드 접합체 및 그의 사용 방법
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
MX2023011480A (es) 2021-04-03 2023-12-06 Ambrx Inc Conjugados anticuerpo anti-her2-fármaco y usos de estos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237885A (en) * 1978-10-23 1980-12-09 Alza Corporation Delivery system with mated members for storing and releasing a plurality of beneficial agents
IL84167A (en) * 1986-10-24 1991-04-15 Southern Res Inst Oral delivery of bioactive agents to and through the peyer's patch by use of microencapsulation
US5075109A (en) * 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5066772A (en) * 1987-12-17 1991-11-19 Allied-Signal Inc. Medical devices fabricated totally or in part from copolymers of recurring units derived from cyclic carbonates and lactides
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
ATE168391T1 (de) * 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
FR2671562B1 (fr) * 1991-01-16 1995-09-15 Oreal Procede de diagnostic d'un etat d'inflammation ou de vieillissement cellulaire des keratinocytes, et necessaire pour la mise en óoeuvre de ce procede.
EP0627911B1 (de) * 1992-02-28 2000-10-25 Board Of Regents The University Of Texas System Photopolymerinierbare, biologisch abbaubare hydrogele als gewebekontaktmaterialien und trägerstoffe für kontrollierte freisetzung
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
CA2075517C (en) * 1992-04-01 1997-03-11 John Wick Transdermal patch incorporating a polymer film incorporated with an active agent
JPH07505813A (ja) * 1992-04-24 1995-06-29 オステオテク，インコーポレイテッド 組織癒着予防装置
CA2086631C (en) * 1992-12-22 1998-10-06 J. Gabriel Michael Oral administration of immunologically active biomolecules and other therapeutic proteins
EP0792161A4 (de) * 1993-07-12 1998-04-29 Virus Res Inst Mikroverkapselte impfstoffe auf hydrogelbasis
BR9507313A (pt) * 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
EP0717999A1 (de) * 1994-12-19 1996-06-26 The University Of Miami Zusammensetzung zur Arzneistoffabgabe

Also Published As

Publication number Publication date
DE69726672T2 (de) 2004-10-07
ES2221916T3 (es) 2005-01-16
EP0830859A2 (de) 1998-03-25
DK1247522T3 (da) 2004-09-27
PT830859E (pt) 2004-04-30
CA2213368C (en) 2008-04-01
DK0830859T3 (da) 2004-04-05
ATE255884T1 (de) 2003-12-15
DE69726672D1 (de) 2004-01-22
DE69729228T2 (de) 2005-05-04
DE69729228D1 (de) 2004-06-24
WO1998006439A1 (en) 1998-02-19
EP0830859B1 (de) 2003-12-10
US5980948A (en) 1999-11-09
EP1247522A1 (de) 2002-10-09
PT1247522E (pt) 2004-10-29
CA2213368A1 (en) 1998-02-16
EP0830859A3 (de) 1998-07-22
EP1247522B1 (de) 2004-05-19
ES2212037T3 (es) 2004-07-16

Similar Documents

Publication Publication Date Title
ATE267006T1 (de) Polyetherester-copolymere als matrixmaterial für die arzneistoffabgabe
CA2304976A1 (en) Delivery of poly(ethylene glycol)-conjugated molecules from degradable hydrogels
CA2355657A1 (en) Biodegradable ph/thermosensitive hydrogels for sustained delivery of biologically active agents
CA2289088A1 (en) Microparticles useful as ultrasonic contrast agents and for delivery of drugs into the bloodstream
EP1656952A3 (de) Polymer-Konjugate von Interferon beta-1A und ihre Verwendungen
ATE241377T1 (de) Pharmazeutische zusammensetzungen für die verzögerte freisetzung von peptiden und verfahren zu deren herstellung
AU1819499A (en) Positively-charged poly{alpha-(omega-aminoalkyl)glycolic acid} for the delivery of a bioactive agent via tissue and cellular uptake
IL126518A0 (en) In sequence delivery of messages
WO2003091337A8 (en) New polyarylates for drug delivery and tissue engineering
ZA9811376B (en) Biodegradable mixed polymeric micelles for gene delivery
PL336576A1 (en) Alpha interferon polyethylene glycol conjugates for treating infections
ZA200204603B (en) Amphiphilic polymers and polypeptide conjugates comprising same.
EE200000219A (et) Kõnepostkast GSM-süsteemis
AU7977798A (en) Poly(ethylene terephthalate) (pet) copolymers containing both 1,4-cyclohexanedimethanol and isophthalic acid moieties
IT1275100B (it) "sistema e disposizione per chiamate da stazioni telefoniche mobili"
DE59810246D1 (de) Zn-Cu-Al Mischoxydkatalysator in Tablettenform
SI0804165T1 (en) Solid medicament form with active agent distributed in polymer material
ES1010911Y (es) Modulo de distribucion y entrega.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1247522

Country of ref document: EP

EEIH Change in the person of patent owner